Accelerating AHSCT research in Australia
24 November 2020
MS Research Australia announces a strategic partnership with St Vincent’s Curran Foundation to advance cellular therapies for MS including AHSCT.
MS Research Australia announces a strategic partnership with St Vincent’s Curran Foundation to advance cellular therapies for MS including AHSCT.
AHSCT for MS has gained increasing interest in recent years, but what is its role against MS? We explore the most common questions about AHSCT.
As 2020 comes to a close, our Chair Associate Professor Desmond Graham shares his insights for the challenging and extraordinary year that was.
Kiss Goodbye to MS is celebrating its biggest year yet! A record-breaking $6.75 million for life-changing MS research has been raised in 2020.
Amber was 33 when she found out she had MS. She gives to MS research in hopes of helping researchers find a cure in her lifetime.
The Board of MS Australia has announced the appointment of Rohan Greenland as the new CEO to guide the newly amalgamated organisation.
The National Health and Medical Research Council has announced $1.4 million in funding for an MS patient-centred digital health care tool – InforMS.
Mayzent (siponimod) the first MS medication approved for secondary progessive MS in Australia, has been listed on the Pharmaceutical Benefits Scheme (PBS).
MS Research Australia has announced the funding of six new incubator grants, which are small grants designed to explore exciting and fresh ideas.